Nivolumab plus ipilimumab improves overall survival in patients

Nivolumab combined with ipilimumab significantly enhances overall survival for patients with untreated unresectable hepatocellular carcinoma compared to lenvatinib or sorafenib. After a median follow-up of 35.2 months, the median overall survival was 23.7 months for nivolumab plus ipilimumab, versus 20.6 months for the other treatments. Although initial higher death rates were observed within the first six months for the combination therapy (hazard ratio 1.65), the long-term survival rates demonstrated its efficacy over time.